Overview
ARGX market data
Price History
ARGX price chart · 1M
- O
- 835.01
- H
- 835.67
- L
- 813.06
- C
- 819.19
- Vol
- 28,903.00
Daily history from May 18, 2017
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $835.01
- Previous Close
- $846.93
- Day High
- $835.67
- Day Low
- $813.06
- 52 Week High
- $1,072.33
- 52 Week Low
- $662.47
- 7 Day Return
- -0.71%
- 30 Day Return
- -16.84%
- 90 Day Return
- -3.29%
- 1 Year Return
- -1.87%
- Daily Notional Volume
- $23.7M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 21.26 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $19.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 30.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $568.40 – $925.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $1,174.83 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $46.9B · P/B 6.72 · P/S 6.50.
Company News
10 captured
argenx Meets Primary Endpoint in Phase II Celiac Disease StudyZacks Investment Research ·
HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeZacks Investment Research ·